BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $261,000 | +1.2% | 3,036 | -5.5% | 0.08% | -10.2% |
| Q3 2021 | $258,000 | -0.4% | 3,212 | 0.0% | 0.09% | -2.2% |
| Q2 2021 | $259,000 | -7.2% | 3,212 | -3.0% | 0.09% | -17.4% |
| Q1 2021 | $279,000 | +13.4% | 3,312 | +8.2% | 0.11% | +7.9% |
| Q4 2020 | $246,000 | -37.6% | 3,062 | -4.7% | 0.10% | -45.4% |
| Q3 2020 | $394,000 | +42.2% | 3,212 | 0.0% | 0.18% | +22.5% |
| Q2 2020 | $277,000 | +4.9% | 3,212 | -1.4% | 0.15% | -14.2% |
| Q1 2020 | $264,000 | -1.9% | 3,257 | +1.4% | 0.18% | +6.0% |
| Q4 2019 | $269,000 | -25.3% | 3,212 | -21.9% | 0.17% | +1.8% |
| Q3 2019 | $360,000 | +5.0% | 4,112 | -1.8% | 0.16% | -25.9% |
| Q2 2019 | $343,000 | +4.6% | 4,187 | -0.7% | 0.22% | -5.6% |
| Q1 2019 | $328,000 | +18.4% | 4,215 | 0.0% | 0.23% | +1.3% |
| Q4 2018 | $277,000 | -15.8% | 4,215 | -1.2% | 0.23% | -5.7% |
| Q3 2018 | $329,000 | +4.4% | 4,265 | 0.0% | 0.24% | +10.9% |
| Q2 2018 | $315,000 | +13.7% | 4,265 | 0.0% | 0.22% | +6.3% |
| Q1 2018 | $277,000 | +0.4% | 4,265 | 0.0% | 0.21% | -1.9% |
| Q4 2017 | $276,000 | +3.0% | 4,265 | 0.0% | 0.21% | -3.7% |
| Q3 2017 | $268,000 | -8.2% | 4,265 | -11.6% | 0.22% | -10.6% |
| Q2 2017 | $292,000 | +32.1% | 4,823 | +13.1% | 0.24% | +67.8% |
| Q1 2017 | $221,000 | +16.9% | 4,265 | 0.0% | 0.15% | +16.8% |
| Q4 2016 | $189,000 | – | 4,265 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |